Margin repair shows early signs of stability
- Humana is built around Medicare Advantage, where it collects premiums and pays member medical bills.
- Management plans to exit plans affecting 600,000 members in 2027 to restore profitability.
- Q2 2026 showed early signs of stabilization, with inpatient medical costs coming in slightly favorable.
- CenterWell is growing, but continues to face integration costs and risk model pressures.
- The possible recovery path hinges on retaining the right members after the 2027 benefit cuts.
A high stakes execution phase
Humana is in the middle of a painful transition. The main issue has been simple. Medical claims are eating too much of the premium dollars it collects. In early 2026, the Insurance benefit ratio spiked to 89.4 percent. The company grew its Medicare Advantage membership, but new members came with higher medical costs.
The bear case rests on disruption. To fix margins, management announced it will exit certain 2027 plans, affecting roughly 600,000 members. If rivals offer better benefits, Humana could lose those members permanently, shrinking its revenue base. On top of that, CenterWell faces margin pressure from new risk models and integration costs.
The bull case is seeing early signs of hope. During Q2 2026, management noted that medical cost trends stabilized in the 7 to 8 percent range, with slight favorability in inpatient costs. Humana is also improving its operational Star Ratings metrics, which could help win back quality bonus payments by 2028. If Humana can recapture a large portion of the exited 600,000 members into higher performing plans, the stock has room to recover.
Premiums in, claims out
Humana makes most of its money by selling health plans. The biggest pool is Medicare Advantage, a private plan option for people on Medicare. Humana gets premiums, including payments tied to government programs, and then pays doctors, hospitals, drug costs, and member benefits.
The key profit lever is the benefit ratio. A lower ratio means Humana keeps more premium dollars after paying medical costs. A higher ratio means claims are taking more of the money. After severe pressure in Q1 2026, cost trends started tracking in line with expectations by Q2.
CenterWell is the services side. It includes pharmacy solutions, primary care, and home solutions. It serves Humana members and outside payors, but it is tied closely to the insurance book. The idea is to manage care better and lower costs over time.
That model breaks when funding, plan pricing, member mix, and medical use do not line up. Star Ratings pressure is also important because lower rated Medicare Advantage plans can receive lower quality bonus payments from CMS. Humana disclosed that about 25 percent of its Medicare Advantage members were in plans rated 4-star or higher for 2025, a massive drop from 94 percent based on 2024 ratings.
Medicare first, services second
Individual Medicare Advantage
This is Humana’s core product. It is undergoing a major margin reset, with 600,000 members facing plan exits in 2027.
Group Medicare Advantage
These plans are sold through group accounts and provide a more stable, though smaller, membership base.
Medicare stand-alone PDP
These are prescription drug plans for Medicare members. The economics are sensitive to federal benefit design and drug costs.
Medicaid, state-based contracts, and military services
These government linked lines add scale and contract revenue. They carry different margin profiles than Medicare Advantage.
CenterWell pharmacy solutions
This business fills and manages prescriptions. Higher specialty pharmacy volume helps revenue but can pressure the cost ratio.
CenterWell primary care and home solutions
These services are meant to improve care and lower medical use over time. Recent acquisitions add growth but also bring integration costs.
Two segments, one big driver
The mix uses early 2026 external segment revenue. Insurance is almost all of the external revenue base, while CenterWell is larger internally because it also sells services to Humana’s Insurance segment.
What could go wrong
Plan exit disruption
High impact · Medium oddsHumana is targeting plan exits for 2027 that will impact about 600,000 members. Management hopes to recapture a significant portion of them in other plans, but if retention falls short, the revenue base could be materially impaired.
Medical costs outrun pricing
High impact · Medium oddsWhile Q2 2026 showed some stabilization in inpatient costs, overall drug and medical costs remain high. If the recent stabilization is temporary, profit pressure will resume.
Star Ratings bonus hit
High impact · High oddsHumana saw a drastic drop in members enrolled in 4-star plans for 2025. The company says this will hurt 2026 quality bonus payments. Lower bonus dollars make pricing and benefits harder.
CenterWell margin reset
Medium impact · High oddsCenterWell faces operating cost pressure from the v28 risk model and acquisition integration costs. If mitigation work fails, the segment may not deliver the profitability investors expect.
In one breath
What does Humana do?
Humana sells health insurance, mainly Medicare Advantage plans, and runs CenterWell healthcare services. CenterWell includes pharmacy, primary care, and home solutions.
Why is Humana under pressure?
Medical costs have taken a larger share of premium revenue. The company is now having to exit certain plans to restore its profit margins.
What could improve the Humana story?
The clearest path is successfully navigating the 2027 Medicare Advantage repricing. If Humana can cut benefits without losing too many members to competitors, profits could recover.
